Welcome to our dedicated page for SciSparc Ltd. SEC filings (Ticker: SPRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SciSparc Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SciSparc Ltd.'s regulatory disclosures and financial reporting.
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reports the launch and progression of a Phase IIb clinical trial of SCI-110 at the Yale Child Study Center for adults with Tourette Syndrome. SCI-110 combines dronabinol with palmitoylethanolamide in a single oral dosage form aimed at reducing tics while limiting side effects.
The multicenter study also runs at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel and builds on Phase IIa results that showed an average 21% tic reduction across participants on the Yale Global Tic Severity Scale. The Phase IIb trial is randomized, double-blind, placebo-controlled and cross-over, enrolling patients aged 18–65 and assessing tic severity changes at weeks 12 and 26.
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reports a technological milestone for NeuroThera’s quantum sampling workflow platform for clinical trials data analytics. The platform has demonstrated a complete end-to-end hybrid quantum-classical workflow in a quantum simulation environment using real-world clinical data.
The workflow integrates secure data ingestion and preparation, quantum-enabled analytical processing, and generation of biologically and clinically interpretable insights. It is designed to handle complex, high-dimensional biomedical datasets and apply quantum-inspired and quantum-enabled methods. Ongoing development plans include scaling supported datasets, optimizing quantum algorithms, and running performance studies, advanced through CliniQuantum Ltd., in which NeuroThera holds 54.01%.
SciSparc Ltd. announced that its board has decided to target the agentic artificial intelligence market and will establish a Scientific Advisory Board focused on AI and cybersecurity. The company is evaluating opportunities and holding discussions with several agentic AI companies.
Subsidiary NeuroThera Labs Inc. reported successful internal validation of a proprietary quantum sampling workflow for clinical trial data analysis, built on an S&P 500 company’s hybrid quantum-classical computing platform. The platform is being advanced through CliniQuantum, a quantum-focused initiative in which NeuroThera holds 54.01%.
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reported the initiation of a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a proprietary cannabinoid-based treatment candidate for adult Tourette Syndrome.
The randomized, double-blind, placebo-controlled, cross-over study will evaluate daily oral SCI-110 in patients aged 18-65, with primary endpoints based on changes in tic severity on the Yale Global Tic Severity Scale at weeks 12 and 26 versus baseline. The multicenter trial also includes the Yale Child Study Center in Connecticut and Tel Aviv Sourasky Medical Center in Israel, building on prior Phase IIa data that showed an average tic reduction of 21%.
SciSparc Ltd. executive Adler Oz, the CEO and CFO, updated his initial insider ownership report. The amendment clarifies that his position includes 10,000 Ordinary Shares issuable from restricted share units vesting in quarterly installments of 1,250 shares through December 18, 2027, and 1,058 Ordinary Shares issuable from additional RSUs vesting in equal quarterly installments of 132 shares through June 20, 2026. The amendment also restates the derivative holdings table, showing a stock option for 6 Ordinary Shares with an exercise price of 31941.0000 and expiration on January 3, 2028. Following the reported holdings, Oz has 11,058 Ordinary Shares reported as directly owned, including the RSUs described.
SciSparc Ltd. director Revach Moshe filed an amended initial ownership report updating his beneficial holdings. Moshe now reports 3,649 Ordinary Shares directly owned, including 3,333 Ordinary Shares issuable from restricted share units (RSUs) vesting in quarterly installments of 417 shares through December 18, 2027, and 316 Ordinary Shares issuable from RSUs vesting in equal quarterly installments of 40 shares through June 20, 2026. Each RSU represents the right to receive one Ordinary Share. In addition, Moshe holds a stock option to acquire 1 Ordinary Share at an exercise price of 31,941, expiring January 3, 2028.
SciSparc Ltd. director Shay Amnon Ben filed an amended initial ownership report updating his equity holdings. The amendment states that he beneficially owns securities representing 3,649 Ordinary Shares, all issuable upon vesting of restricted share units that vest in quarterly installments through June 20, 2026 and December 18, 2027. He also holds a stock option giving the right to purchase 1 Ordinary Share at an exercise price of 31649.0000, expiring on January 3, 2028. The amendment replaces Table I and Table II of the prior Form 3 as to these ownership details.
SciSparc Ltd. updated the initial insider ownership report for director Alon Dayan. The amendment reflects beneficial ownership of 3,649 Ordinary Shares, including 3,333 RSUs vesting in quarterly installments of 417 shares through December 18, 2027, and 316 RSUs vesting in quarterly installments of 40 shares through June 20, 2026. It also adds a stock option for 1 Ordinary Share at an exercise price of 31941.0000, expiring on January 3, 2028, which was fully vested on April 21, 2024.
SciSparc Ltd. director Liat Sidi filed an amended Form 3 to update her initial ownership report. The amendment revises the total number of securities beneficially owned and restates Table II. Following this update, she holds 3,649 Ordinary Shares directly and a stock option over 1 Ordinary Share. Her holdings include 3,333 Ordinary Shares issuable from restricted share units vesting in quarterly installments of 417 Ordinary Shares through December 18, 2027, and 316 Ordinary Shares issuable from restricted share units vesting in equal quarterly installments of 40 Ordinary Shares through June 20, 2026. Each RSU represents the right to receive one Ordinary Share.
SciSparc Ltd. director Weiss Amitay reports initial beneficial ownership details in an amended Form 3. Amitay holds 11,058 Ordinary Shares directly, including RSUs for 10,000 Ordinary Shares vesting in quarterly installments of 1,250 shares through December 18, 2027, and RSUs for 1,058 Ordinary Shares vesting in quarterly installments of 132 shares through June 20, 2026. Amitay also holds a stock option to buy 6 Ordinary Shares at an exercise price of 31,941.0000 per share, expiring January 3, 2028. The amendment restates the RSU footnote and Table II of the initial ownership report without reporting new buy or sell transactions.